| Naziv: | Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome |
Autori  : | Schwartz, GG; ...; Dilić, Mirza; ...; Ristić, Arsen D.   ; ...; Simić, Dragan V. ; Ivanović, Nikola; Davidović, Goran T. ; Tasić, Nebojša M.;
Ašanin, Milika R. ; Stojić, Stevo; Apostolović, Svetlana R. ; Ilić, Stevan N.; Putniković, Biljana ; Stanković, Aleksandar; Arandjelovic, Aleksandra C. ; Radovanović, Slavica ; Balinovac, Jovan; Dinčić, Dragan V. ; Seferović, Petar M. ; Dodić, Slobodan S.; Dimković, Siniša ; ...; (broj, koautora 1390);
|
Godina: | 2018 |
Publikacija: | The New England Journal of Medicine |
ISSN: | 0028-4793 e1533-4406 New England Journal of Medicine Pretraži identifikator |
Izdavač: | Massachusetts Medical Society, Boston |
Tip rezultata: | Naučni članak |
Kolacija: | vol. 379 br. 22 str. 2097-2107 |
DOI: | 10.1056/NEJMoa1801174 |
WoS-ID: | 000451402500005 |
Scopus-ID: | 2-s2.0-85057337718 |
URI: | https://enauka.gov.rs/handle/123456789/818769 |
URL: | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1801174?articleTools=true
https://www.zora.uzh.ch/id/eprint/162737/1/Alirocumab_and_cardiovascular_outcomes.pdf |
Projekat: | Sanofi
Regeneron Pharmaceuticals
Cerenis
Resverlogix
Roche Holding
Medicines Company
Bayer AG
MerckMerck & Company
Amarin
Servier
Baxter
AstraZeneca
Bristol-Myers Squibb
EisaiEisai Inc
Ethicon; |
Izvor metapodataka: | (Preuzeto iz Nasi u WoS) |
M-kategorija: | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
